Találati lista | Tudóstér

001-es BibID:	BIBFORM119513
Első szerző:	Charles-Schoeman, Christina
Cím:	Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-enriched Rheumatoid Arthritis Patients / Christina Charles-Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, Cunshan Wang, Ted R. Mikuls, All-shine Chen, Carol A. Connell, John C. Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz
Dátum:	2024
ISSN:	2326-5191 2326-5205
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Arthritis & Rheumatology. - [Epub ahead of print] (2024). -
További szerzők:	Fleischmann, Roy Mysler, Eduardo Greenwald, Maria Ytterberg, Steven R. Koch, Gary G. Bhatt, Deepak L. Wang, Cunshan Mikuls, Ted R. Chen, All-shine Connell, Carol A. Woolcott, John C. Menon, Sujatha Chen, Yan Lee, Kristen Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM088829
Első szerző:	Pavelka, Karel
Cím:	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate : a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients / Pavelka Karel, Szekanecz Zoltán, Damjanov Nemanja, Anić Branimir, Tomšič Matija, Mazurov Vadim, Maksimovic Marija, Nagy Orsolya, Świerkot Jerzy, Petranova Tzvetanka, Veldi Tiina, Baranauskaitè Asta, Codreanu Catalin, Andersone Daina, Fleischmann Roy
Dátum:	2020
ISSN:	1745-1981 1740-4398
Megjegyzések:	Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc analysis of SELECT-COMPARE reports the efficacy and safety of upadacitinib in Central and Eastern European (CEE) patients. Methods: Patients were randomized 2:2:1 to upadacitinib 15 mg once daily, placebo, or adalimumab 40 mg every other week, and continued MTX. Efficacy and safety were assessed through 48 weeks. Primary endpoints were the achievement of ?20% improvement in American College of Rheumatology response criteria and Disease Activity Score in 28 joints with C-reactive protein <2.6 responses at week 12 for upadacitinib versus placebo. No statistical comparisons were conducted. Results: A total of 596 patients from 12 CEE countries were randomized. At week 12, a numerically greater proportion of patients receiving upadacitinib versus placebo or adalimumab achieved ?20% improvement in American College of Rheumatology response criteria (72% versus 33% and 59%), Disease Activity Score in 28 joints with C-reactive protein <2.6 (26% versus 4% and 11%), low disease activity and remission, and improved physical function, with results maintained over 48 weeks. Upadacitinib treatment numerically inhibited structural progression versus placebo at week 26. Serious infection and herpes zoster rates were numerically higher with upadacitinib versus adalimumab (2.7 versus 1.7 and 2.3 versus 1.1 events/100 patient-years, respectively) over 48 weeks. Conclusion: Consistent with the global population of patients with rheumatoid arthritis and an inadequate response to MTX, in CEE patients, upadacitinib 15 mg demonstrated clinical and functional improvements versus placebo and adalimumab, radiographic improvements versus placebo, and reasonable safety, over 48 weeks.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Eastern Europe rheumatoid arthritis safety treatment efficacy upadacitinib
Megjelenés:	Drugs in Context. - 9 (2020), p. 1-15. -
További szerzők:	Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Damjanov, Nemanja Anic, Branimir Tomšič, Matija Mazurov, Vadim Maksimovic, Marija Nagy Orsolya Świerkot, Jerzy Petranova, Tzvetanka Veldi, Tiina Baranauskaitè, Asta Codreanu, Catalin Andersone, Daina Fleischmann, Roy
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM117872
035-os BibID:	(WoS)001142644000003 (Scopus)85182237892
Első szerző:	Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:	Efficacy and safety of JAK inhibitors in rheumatoid arthritis : update for the practising clinician / Zoltán Szekanecz, Maya H. Buch, Christina Charles-Schoeman, James Galloway, George A. Karpouzas, Lars Erik Kristensen, Steven R. Ytterberg, Attila Hamar, Roy Fleischmann
Dátum:	2024
ISSN:	1759-4790 1759-4804
Megjegyzések:	Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about their safety, particularly following the issuance of guidance by regulatory agencies advising caution in their use in certain patients. The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events (MACEs), venous thromboembolism, malignancies or infections (other than herpes zoster) with a JAK inhibitor versus a biologic DMARD. In the ORAL Surveillance trial, which enrolled patients >50 years of age with ?1 cardiovascular risk factor, tofacitinib was statistically inferior to TNF inhibitors for the occurrence of MACEs and malignancy. Further post hoc analysis of the data revealed that an age of ?65 years, a high baseline cardiovascular risk, a history of smoking, sustained inflammation, disease activity and suboptimal treatment of cardiovascular comorbidities all increase the risk of these outcomes. The guidance issued by regulatory agencies should be carefully considered to ensure appropriate and safe treatment of patients with RA without undertreatment of patients who might benefit from JAK inhibitor, as well as biologic, treatment. As always, the risks associated with the use of these agents, treatment goals, costs and patient preferences should be discussed with the patient.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Nature Reviews Rheumatology. - 20 : 2 (2024), p. 101-115. -
További szerzők:	Buch, Maya H. Charles-Schoeman, Christina Galloway, James Karpouzas, George A. Kristensen, Lars Erik Ytterberg, Steven R. Hamar Attila Béla (1990-) (általános orvos) Fleischmann, Roy
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: